← Oncology Approval Tracker

FDA DECISION ·

Tecvayli

teclistamab-cqyv · Janssen Biotech

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Mar 5, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least four lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

LAMPGEN ANALYSIS

Why it matters

The initial indication brings a BCMA-directed bispecific T-cell engager to a heavily pretreated myeloma population.

What research teams should watch

Reconstruct therapy history and coordinate step-up dosing, infection monitoring, and escalation for cytokine release syndrome.

PRIMARY RECORDS

Sources